OXiGENE, Inc.
701 Gateway Boulevard
Suite 210
South San Francisco,
CA 94080
United States - Map
Phone: 650-635-7000
Fax: 650-635-7001
Website: http://www.oxigene.com
OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops therapeutics primarily to treat cancer. The company primarily focuses on the development of vascular disrupting agents that disable and destroy abnormal blood vessels, which provide solid tumors a means of growth and survival, and also are associated with visual impairment in various ophthalmological diseases and conditions. Its principal product candidate includes ZYBRESTAT, a reversible tubulin binding agent, which is in Phase II clinical trials for the treatment of ovarian cancer, anaplastic thyroid cancer, medullary thyroid cancer, stage IV papillary thyroid cancer, and stage IV follicular thyroid cancer. The company is also developing ZYBRESTAT for ophthalmological diseases and conditions that are characterized by abnormal blood vessel growth within the eye that result in loss of vision. In addition, it is developing OXi4503 for the treatment of acute myelogenous leukemia and myelodysplastic syndromes solid tumors with hepatic burden. The company was founded in 1988 and is headquartered in South San Francisco, California. Key Statistics
| |
| | Pay | Exercised | Dr. Peter J. Langecker M.D., Ph.D.,
62
Chairman, Chief Exec. Officer and Pres | 351.00K | 0.00 | Ms. Barbara Riching ,
54
Chief Financial Officer and Principal Accounting Officer | 218.00K | 0.00 | Ms. Shari Annes ,
Exec. Officer of Investor Relations | N/A | N/A | Dr. Yuval Binur Ph.D.,
Exec. VP of Financial | N/A | N/A | Lisa Powell ,
Assistant Sec. | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.04(1.21%) May 24, 3:23PM EDT